Zymeworks announces director Lota Zoth will not seek re-election; nominates oncology leader Nancy Davidson to board

Zymeworks Inc.

Director Lota Zoth not standing for re-election at Dec. 7, 2023 annual meeting; will continue as lead independent director until term ends.
Board nominates Dr. Nancy Davidson for election; if elected, she serves as Class II director with term through 2026 annual meeting.
Davidson is EVP for Clinical Affairs at Fred Hutchinson Cancer Center, past president of ASCO and AACR, bringing deep oncology expertise.
If elected, Davidson will receive an initial stock option grant for 50,000 shares under standard non-employee director compensation.
Company is targeting zanidatamab approval/commercialization and five IND filings before end of 2027.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lota Zoth

Director

ZYME · Zymeworks Inc.

Effective: 2023-12-07
Filed: October 16, 2023, 7:59 PM ET

Ms. Lota Zoth, a member of the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) notified the Company of her decision not to stand for re-election to the Board at the Company’s next annual meeting of stockholders to be held on or about December 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lota Zoth departed as Director at Zymeworks Inc..

Action: not stand for re-election
Role: Director

Exact text from the filing

Ms. Lota Zoth, a member of the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) notified the Company of her decision not to stand for re-election to the Board at the Company’s next annual meeting of stockholders to be held on or about December 7, 2023.

View on SEC.gov

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-256934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.